BIIB111
Sponsors
Biogen Idec Research Limited, Biogen, NightstaRx Ltd, a Biogen Company
Conditions
ChoroideremiaChoroideremia (CHM)
X-Linked Retinitis Pigmentosa (XLRP)X-Linked Retinitis Pigmentosa
Phase 2
Phase 3
Efficacy and Safety of BIIB111 for the Treatment of Choroideremia
CompletedNCT03496012
Start: 2017-12-11End: 2020-12-01Updated: 2023-12-07
Long-term Safety and Efficacy Follow-up of BIIB111 for the Treatment of Choroideremia and BIIB112 for the Treatment of X-Linked Retinitis Pigmentosa
CompletedNCT03584165
Start: 2018-06-04End: 2026-06-22Updated: 2026-07-06
A Long-term Follow-up Study to Evaluate the Safety and Efficacy of Retinal Gene Therapy in Subjects with Choroideremia Previously Treated with Adeno-Associated Viral Vector Encoding Rab Escort Protein-1 (AAV2-REP1) and in Subjects with X-Linked Retinitis Pigmentosa Previously Treated with Adeno-Associated Viral Vector Encoding RPGR (AAV8-RPGR) in an Antecedent Study (SOLSTICE)
Not yet recruitingCTIS2023-507994-16-00
Target: 54Updated: 2025-12-12